Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.

Autor:in

Baumgartner, Christian; Gleixner, Karoline V; Peter, Barbara; Ferenc, Veronika; Gruze, Alexander; Remsing Rix, Lily L; Bennett, Keiryn L; Samorapoompichit, Puchit; Lee, Francis Y; Pickl, Winfried F; Esterbauer, Harald; Sillaber, Christian; Superti-Furga, Giulio; Valent, Peter;

Schlagwörter

Apoptosis/drug effects; Cell Division/drug effects*; Cell Line, Tumor; Cell Survival/drug effects*; DNA Replication/drug effects; Eosinophils/drug effects; Eosinophils/enzymology; Eosinophils/physiology*; Flow Cytometry; Humans; Hypereosinophilic Syndrome/drug therapy*; Protein Kinase Inhibitors/pharmacology*; Pyrimidines/pharmacology*; Sequence Deletion; Thiazoles/pharmacology*; Thymidine/metabolism; mRNA Cleavage and Polyadenylation Factors/drug effects; mRNA Cleavage and Polyadenylation Factors/physiology*;

ISSN/eISSN

0301-472X -

WoS ID

WOS:000259897700003